DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and twenty-one approved drugs.

There are seventy-five US patents protecting TEVA drugs. There are forty-three tentative approvals on TEVA drugs.

There are eight hundred and seventy-one patent family members on TEVA drugs in forty-nine countries and six hundred and eleven supplementary protection certificates in fifteen countries.

Summary for Teva

International Patents:	871
US Patents:	75
Tradenames:	480
Ingredients:	418
NDAs:	721
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	076269-001	Jun 18, 2004	AB1	RX	No	No
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-003	Apr 3, 2017		RX	Yes	Yes
Teva	OXAPROZIN	oxaprozin	TABLET;ORAL	075849-001	Jul 3, 2002	AB	RX	No	No

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-002	Approved Prior to Jan 1, 1982	3,546,226
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-001	May 16, 2006	5,457,133
Teva Branded Pharm	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-001	Approved Prior to Jan 1, 1982	3,546,226

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	0.5 mg and 1 mg		2010-05-17
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Drugs

Country	Patent Number	Estimated Expiration
South Korea	20120117740
Denmark	2200593
Japan	2017132773

Supplementary Protection Certificates for Teva Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0810209	CA 2007 00017	Denmark		PRODUCT NAME: DARUNAVIR OG ET FARMACEUTISK ACCEPTABELT SALT DERAF
0957929	SPC/GB06/021	United Kingdom		PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
1507558	C300528	Netherlands		PRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral